AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ :VRML ), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, has been invited to participate in Lazard Capital Market's 5th Annual Medical Technology Snowbird Conference. The conference is being held at the Cliff Lodge Snowbird Ski & Summer Resort in Snowbird, Utah from February 27 - March 1, 2013.
Vermillion's Interim CEO Bruce A. Huebner is scheduled to participate in one-on-one meetings with institutional investors to be held throughout the day on Wednesday, February 27, 2013. He will discuss the company's initiatives to drive market adoption of OVA1®, the first FDA-cleared blood test for the pre-surgical diagnosis of ovarian masses using a unique multi-marker algorithm.
For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Lazard representative.
About Lazard Capital Markets
Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets. The company's institutional clients value its focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors. The company's Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, the company's relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides the company with unparalleled global connections. For more information, visit www.lazardcap.com.
Vermillion, Inc. (NASDAQ :VRML ) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.